An investigator-initiated, phase II clinical trial of the peptide-based cancer vaccine targeting WT1, DSP-7888, for colorectal adenomas in familial adenomatous polyposis

ABSTRACT: Interventions: Induction phase: intradermal administration of DSP-7888 dosing emulsion 3.5mg once every 14 days for 2 months (5 times in total) Maintenance phase: intradermal administration of DSP-7888 dosing emulsion 3.5mg once every 28 days for 6 months (6 times in total) Primary outcome(s): Percentage of patients with newly detected polyps of >=5 mm in diameter in the colon and/or rectum Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Fap,Familial Adenomatous Polyposis

PROVIDER: 2613425 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR